Biovail ( BVF) acquired the U.S. rights to Ativan and Isordil from Wyeth ( WYE) for $130 million and annual payments related to a three-year supply agreement. Sales of Ativan and Isordil in the U.S. exceeded $50 million in 2002. Ativan is a benzodiazepine, indicated for managing anxiety disorders. The market for anxiety treatments reached more than $11 billion in 2002. Isordil is a nitrate designed to prevent angina pectoris due to coronary artery disease. Sales of nitrate products were above $360 million last year. "The acquisition of Ativan and Isordil is another example of the execution of Biovail's business model," the pharmaceutical company said in a press release. "These products have tremendous brand equity and strategically complement two of the company's target therapeutic areas." Shares of Biovail were rising 3.4% to $48.22 in recent New York Stock Exchange trading. Wyeth was down 16 cents at $43.69.